Introduction: Minimally invasive approaches are increasingly being used for the conduct of complex surgical procedures. Whether the benefits of minimally invasive approaches compared to thoracotomy for sublobar and lobar lung resection for NSCLC are realized for patients undergoing pneumonectomy is not clear.
Methods: The National Cancer Database was queried for patients who underwent pneumonectomy for NSCLC from 2010 to 2014. Case data from patients who underwent resection by minimally invasive surgery (MIS) were compared with those from patients who received thoracotomy (open) in an intention-to-treat analysis. Associations between potential covariates and treatment were analyzed using the Pearson chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables. Univariable and multivariable logistic models and proportional hazards model were used to assess the effect of surgical approach on 30-day and 90-day mortality and overall survival. Relative prognosis was summarized using odds ratios and hazards ratios estimates and 95% confidence limits.
Results: A total of 4,938 patients underwent pneumonectomy during the study period, of which 755 (15.3%) were completed by MIS. No difference was noted in 30-and 90-day mortality rates for MIS compared to open approaches (6.8% and 12.3% versus 6.7% and 11.9%, respectively; p ¼ 0.9 and 0.86, respectively). Tumor histology and stage characteristics were similar between the two groups. The mean number of lymph nodes examined was higher in the MIS group compared to the open thoracotomy group (17.1 ± 0.4 versus 16.1 ± 0.2, p ¼ 0.034). The conversion rate for the MIS cohort was 36.7%. Surgical approach was not associated with any difference in perioperative mortality with univariable or multivariable analysis. MIS was associated with improved overall survival on univariable analysis, but this was not evident with multivariable analysis.
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lung resection are well accepted. Improved perioperative outcomes with equivalent long-term oncologic outcomes are well documented. [1] [2] [3] [4] [5] [6] [7] Since VATS lobectomy was first described more than 20 years ago, widespread adoption has been methodical, but steady. More than 60% of lobectomies are being performed by VATS as documented within the Society of Thoracic Surgeons -General Thoracic Surgery Database. 8 Literature pertaining to outcomes for robotic-assisted approaches to lung resection is evolving. A report examining robotic-assisted lobectomy and wedge resection showed a similar perioperative safety profile to VATS approaches despite potential drawbacks pertaining to cost and operative time. 9 Whether the benefits of minimally invasive approaches are realized for patients undergoing resection for more complex tumor pathology, including pneumonectomy, is not clear. Although the profound physiologic effects of whole-lung resection may supersede any effects associated with surgical approach, it is reasonable to expect that the advantages realized for minimally invasive lobar and sublobar resections may translate to more extensive operations if oncologic principles are maintained. Despite this, adoption of minimally invasive approaches for pneumonectomy has been slower than for lobectomy. Large, bulky tumor pathology often involving the hilum, fear of catastrophic loss of vascular control at the level of the main pulmonary artery, and avoidance of pneumonectomy related morbidity and mortality contribute to the relatively small level of experience with VATS or robotic-assisted pneumonectomy. Concerns regarding oncologic compromise in these high-risk patients, similar to those dispelled during the introductions of VATS lobectomy, exist as well. Despite these challenges, increasing surgeon experience combined with improved surgical instrumentation and videoscopic technology (high-definition cameras and monitors, including three-dimensional imaging capability) have allowed for the safe implementation of minimally invasive approaches to pneumonectomy.
Little evidence currently exists validating the potential advantages for resecting tumor pathologies requiring pneumonectomy by minimally invasive surgery (MIS). Reports are largely limited to small case series and single-institution experiences. [10] [11] [12] [13] [14] [15] [16] [17] Large multi-institution databases afford the opportunity to examine larger numbers of patients for comparing outcomes where differences may be subtle. Here we report results using the National Cancer Database (NCDB) for patients undergoing whole-lung resection by minimally invasive approaches compared to those undergoing open thoracotomy.
Methods
The NCDB was used as the data source for this study. The NCDB is a joint project of the American Cancer Society and the American College of Surgeons. This large, nationwide database captures incident cancer cases diagnosed or treated at more than 1500 Commission on Cancer-accredited facilities in the United States. Data from more than 30 million cancer patients is abstracted by trained registrars, and the NCDB captures approximately 70% of all newly diagnosed cancer cases yearly. The American College of Surgeons and the Commission on Cancer are not responsible for the statistical methodology used, or the conclusions drawn by investigators analyzing the de-identified data received in the form a Participant User File (PUF) document. 18 The NCDB was queried for patients who underwent pneumonectomy for NSCLC from 2010 to 2014. The selection criteria used to finalize the patient study population are listed in Table 1 . Patients who underwent resection by minimally invasive approaches were compared with those undergoing thoracotomy in an intention-to-treat analysis. Patients who underwent surgery by robotic approaches or VATS, along with those who required intraoperative conversion were included in the MIS group. Patients with no approach specified were excluded. Variables included in the NCDB that are able to be analyzed include patient age, race, sex, grade, histology, analytic stage, Charleson-Deyo score, number of lymph nodes examined, extent of resection (R0, R1, or R2), and the year of diagnosis. Analytic stage refers to the stage coded using the American Joint Committee on Cancer staging manual edition in use during the year in which the case was diagnosed. Variables pertaining to systemic treatment were not evaluated with the exception of timing of treatment. Continuous variables were summarized with means, medians, and standard deviations. Frequencies and cumulative frequencies were used to summarize categorical data.
Associations between potential covariates and treatment were analyzed using the Pearson chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables. Outcome variables analyzed included 30-day and 90-day mortality, as well as overall survival (OS). OS, the primary endpoint, was defined as the time (in months) from diagnosis to death from any cause. Patients alive at the date of last follow-up were censored. Univariable and multivariable logistic models were used to assess the effect of surgical approach on 30-day and 90-day mortality. Model results were summarized using estimates and 95% confidence limits for the odds ratio. Univariable and multivariable proportional hazards models were used to assess the effect of surgical approach on OS. Relative prognosis was summarized using estimates and 95% confidence limits for the hazard ratio. Unadjusted differences in overall mortality based on surgical approach are shown using the Kaplan-Meier method. The log-rank test was used for comparison of survival distributions. All analyses were conducted using SAS v9.4 (Cary, North Carolina) at a significance level of 0.05. 
Univariable and multivariable analyses of clinical variables and their association with perioperative mortality at 30-and 90-days are shown in Tables 3 and 4 . Risk for perioperative mortality at 30 and 90 days was not impacted by surgical approach in either analysis. When clinical variables were analyzed for association with OS with univariable and multivariable analysis, surgical approach with MIS was found to correlate with improved survival on univariable analysis (Table 5) . However, this difference disappears on multivariable analysis. Unadjusted Kaplan Meier estimates show improved 5-year survival and median OS with minimally invasive approaches (Fig. 1) .
Discussion
The results from this review of a large multiinstitution database suggest that approaching pneumonectomy by minimally invasive approaches does not negatively impact perioperative outcomes. Despite a significant conversion rate of more than 30% for the MIS group, the 30-day and 90-day mortality rates for patients were similar in patients undergoing minimally invasive surgery compared to those approached with standard thoracotomy. Outcomes for patients undergoing pneumonectomy are likely multifactorial and may be affected more by overall disease burden and the physiologic strain associated with whole-lung removal rather than surgical stress associated with surgical approach alone. How approaching pneumonectomy by minimally invasive approaches potentially affects long-term outcomes is not known and is difficult to glean from case series and single-institution experiences. Despite inherent limitations, large, multi-institution databases offer the ability to examine enough patients to look for potentially subtle long-term outcome differences. The results we report here suggest that minimally invasive approaches to whole-lung resection do not adversely impact longterm survival. Validating large data sets from multiple institutions is always difficult, but overall 30-day and 90-day mortality rates of 6.7% and 12% are consistent with previously reported outcomes for pneumonectomy. Despite the known risks for perioperative morbidity and mortality, pneumonectomy is sometimes required for the resection of NSCLC. Pneumonectomy has previously been associated with the highest level of relative perioperative risk for patients undergoing surgical resection of NSCLC; therefore, attempts to reduce the morbidity and mortality associated with the procedure are necessary. 19 Reports showing improved outcomes with sleeve resection over pneumonectomy exist and are well accepted, but there are situations when whole-lung resection is required to achieve R0 resection (complete resection where all margins are grossly and microscopically negative). 20 While adoption of minimally invasive approaches has continued to steadily increase for sublobar and lobar resections, thoracotomy remains the standard for wholelung resection. Reasons for this likely involve the known cardiopulmonary challenge to the patient, the potential for catastrophic complications working on hilar structures, and large bulky tumor/lymph node pathology. Similar concerns regarding the oncologic validity of approaching complex tumor pathology by minimally invasive approaches that plagued the adoption of VATS lobectomy exist as well. Despite these challenges, potential benefits of minimally invasive approaches to lung resection have resulted in surgeons approaching more complex tumor pathology, requiring more complex procedures by VATS and robotic-assisted approaches. 21, 22 These include sleeve resection with airway reconstruction, chest wall resection, as well as pneumonectomy. The potential benefits of minimally invasive pneumonectomy are not determined purely on hypotheses formulated based on outcomes from lobar and sublobar resections. Animal experiments show potential benefits for thoracoscopic approaches to pneumonectomy. Liu et al. 23 studied acute phase reactive proteins in dogs undergoing whole-lung resection by VATS compared to thoracotomy. Despite longer operative times, serum markers of inflammation including C-reactive protein on postoperative day (POD) 3 and the leukocyte count on POD 1 were significantly lower for the VATS cohort. 23 Similar findings were noted in pig experiments comparing VATS to thoracotomy for pneumonectomy. C-reactive protein and interleukin-6 measurements were significantly lower in the VATS group compared to the open-thoracotomy group on POD 1, and serum cortisol levels for the thoracotomy group were significantly elevated compared to VATS at 4 hours and 1 day after surgery. 24 Beyond the laboratory setting, actual results for thoracoscopic pneumonectomy are largely limited to case reports and case series based on single-institution experiences. The first VATS pneumonectomy (left) was reported by Walker in 1994, followed a year later by results from a series of six patients. 10, 11 Since those initial reports, multiple additional case reports or small case series have been reported. [12] [13] [14] [15] [16] [17] Gonzales-Rivas reported the first successful completion of single incision pneumonectomy in 2013, and another report exists for an awake nonintubated pneumonectomy (for nonmalignant pathology). 14, 15 The available evidence shows minimally invasive approaches to be safe from a perioperative standpoint. In 2016, Liu et al. 13 reported on 32 patients who underwent VATS pneumonectomy compared to 64 patients who underwent conventional thoracotomy. Despite requiring longer operative times (187.5 minutes versus 146.3 minutes), patients undergoing VATS pneumonectomy experienced no difference in transfusion rates, estimated blood loss, hospital length of stay, dissected lymph node numbers, or lymph node stations. Overall complication rates were similar for both VATS and thoracotomy groups at 20.0% and 22.5%, respectively.
We have previously reported our single-institution experience with thoracoscopic pneumonectomy. 17 The retrospective review of 101 consecutive patients undergoing pneumonectomy over a 10-year period included 37 approached via standard thoracotomy, whereas 64 were attempted by VATS. Intraoperative conversion was required in 26% of cases (n ¼ 17) with a learning curve noted as the percentage of successfully completed VATS cases rose from 26% to 63% during the second half of the series. There were no intraoperative deaths from bleeding or technical errors, and in all cases the main pulmonary artery was controlled safely. Clinical stage was lower in the VATS group, but more upstaging occurred in this group. Median survival for pathologic stage III and IV patients was higher for patients approached by VATS. 17 Limitations of this study and those involving large multi-institution databases in general are numerous and include the retrospective nature and inability to verify uniform consistency in operative techniques for the groups. Specific preoperative comorbidity information is not available, and a lack of detailed data regarding patient characteristics such as cardiopulmonary status including pulmonary function tests are limitations; therefore, it is difficult to adjust for these factors, although it is not unreasonable to assume that patients undergoing whole-lung resection are thoroughly evaluated by an experienced thoracic surgeon. Inability to control for patient selection bias and surgeon variance is an inherent limitation of this retrospective evaluation of multi-institution data.
Another limitation in comparing these two surgical groups is the difficulty in accounting for surgeon bias when faced with choosing between pneumonectomy versus attempted complex bronchoplastic or arterial resection/reconstruction performed by thoracotomy. The difficulty in assessing whether complex bronchoplastic resection is feasible by VATS creates scenarios where surgeons may opt for pneumonectomy that can be accomplished by minimally invasive approaches in lieu of converting to thoracotomy. Lastly, validation of data is always a challenge when using multi-institution data sets, but the 30-and 90-day mortality results for the patients reported are consistent within accepted standards for pneumonectomy.
Conclusion
Pneumonectomy performed by minimally invasive approaches does not compromise perioperative mortality or long-term outcomes for patients with NSCLC. Further investigation into the impact of minimally invasive approaches on perioperative outcomes is warranted.
